Study backs test for predicting heart disease:
This article was originally published in Clinica
Executive Summary
UK company Omega Diagnostics has reported that the first independent clinical trial of its CardioPath test for predicting coronary heart disease has produced positive results. Middle-aged men who tested positive on the assay were linked with a five-to-six times increased risk of developing a coronary event, according to a study by the UK's Medical Research Council Epidemiology and Medial Care Unit in London. The test prototype is currently in an open enzyme immunoassay format and detects the activation of complement, a group of proteins involved in the body's immune system, said Alloa-based Omega.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.